Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer

Kai Yuan(China Pharmaceutical University), Peng Yang(Chinese Academy of Medical Sciences & Peking Union Medical College)
Nature Communications
May 25, 2022
Cited by 18


Related Papers